Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000669952 | SCV000794755 | uncertain significance | Usher syndrome type 2A; Retinitis pigmentosa 39 | 2017-10-16 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002531241 | SCV003524117 | pathogenic | not provided | 2023-10-17 | criteria provided, single submitter | clinical testing | This sequence change replaces aspartic acid, which is acidic and polar, with glycine, which is neutral and non-polar, at codon 347 of the USH2A protein (p.Asp347Gly). This variant is present in population databases (rs762384558, gnomAD 0.0009%). This missense change has been observed in individual(s) with Usher syndrome (PMID: 25558175, 33576794). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 554336). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt USH2A protein function. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. |
Baylor Genetics | RCV003472120 | SCV004200723 | likely pathogenic | Retinitis pigmentosa 39 | 2024-01-05 | criteria provided, single submitter | clinical testing |